The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).
The present disclosure provides methods for treating hepatitis D virus (HDV) infection and/or an HDV-associated disease using combination therapies, and related kits and compositions for use in such methods. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).
Provided herein are engineered polypeptides (e.g., Fc polypeptides, Fc polypeptide fragments, Fc fusion proteins, antibodies, and the like) that comprise a variant of an IgG Fc polypeptide (or a portion or fragment thereof), which variants (and the polypeptides that comprise these variants) have one or more improved characteristics over known Fc polypeptides.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection in a subject. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus and/or SARS-CoV-2 infection.
The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection, e.g., in a subject having or at risk for developing COVID-19, using an antibody (or antigen-binding fragment) compositions. Disclosed methods include prophylaxis against SARS-CoV-2 infection or transmission, as well as treatment of a subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.
The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and biological preparations and medicinal
infusions for prevention and treatment of infectious
diseases and disorders, viral diseases and disorders, and in
the field of oncology. Research and development in the pharmaceutical and
biotechnology fields; development of pharmaceutical
preparations and medicines; pharmaceutical, biomedical,
biological therapeutic research services; research in the
field of pharmaceutical and biologic therapeutic
preparations; pharmaceutical research and development;
providing scientific research information in the field of
pharmaceuticals, biomedicine, clinical trials, and
post-market trials. Providing health and medical information; providing
information relating to the diagnostic, prophylactic and
therapeutic properties of pharmaceutical preparations and
biologic preparations for the prevention and treatment of
diseases, disorders, and conditions; medical and
pharmaceutical consultation.
The present disclosure provides methods for producing cytomegalovirus (CMV) viral vectors. The present disclosure also provides methods for modifying host cells for use in producing CMV viral vectors.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical and biological preparations and medicinal infusions for prevention and treatment of infectious diseases and disorders, viral diseases and disorders, and in the field of oncology. (1) Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines; pharmaceutical, biomedical, biological therapeutic research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical research and development; providing scientific research information in the field of pharmaceuticals, biomedicine, clinical trials, and post-market trials.
(2) Providing health and medical information; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders, and conditions; medical and pharmaceutical consultation.
10.
MODULATORS OF CORONAVIRUS 3C-LIKE PROTEASE AND USES THEREOF
The present disclosure provides modulators, such as inhibitors, of 3C-like (3CL) protease and formulations thereof, wherein said modulators and formulations thereof are useful for treating diseases and disorders associated with a coronavirus 3CL protease and inhibiting the replication of coronaviruses.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Antiviral pharmaceuticals; immunotherapy pharmaceuticals;
antiviral pharmaceuticals for use in the treatment of
infectious diseases and disorders and in the field of
oncology. Research and development in the pharmaceutical and
biotechnology fields; development of pharmaceutical
preparations and medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Antiviral pharmaceuticals; immunotherapy pharmaceuticals;
antiviral pharmaceuticals for use in the treatment of
infectious diseases and disorders and in the field of
oncology. Research and development in the pharmaceutical and
biotechnology fields; development of pharmaceutical
preparations and medicines.
The disclosure relates to human papillomavirus (HPV) antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
The disclosure relates to human papillomavirus (HPV) antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.
The instant disclosure provides antibodies and antigen-binding fragments that can bind to a RSV and/or MPV fusion glycoprotein and can neutralize a RSV and/or MPV infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a RSV and/or MPV infection.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Antiviral pharmaceuticals; immunotherapy pharmaceuticals; antiviral pharmaceuticals for use in the treatment of infectious diseases and disorders and in the field of oncology. (1) Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Antiviral pharmaceuticals; immunotherapy pharmaceuticals; antiviral pharmaceuticals for use in the treatment of infectious diseases and disorders and in the field of oncology. (1) Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines.
18.
ANTIBODIES AGAINST STAPHYLOCOCCUS ANTIGENS AND METHODS OF USING THE SAME
StaphylococcusStaphylococcie.g.S. aureusS. aureus) and, in certain embodiments, by one or more other bacteria. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a bacterial infection.
The disclosure provides sulfoximine based modulators of Formula (I), or pharmaceutically acceptable salts thereof, for the inhibition of the oligosaccharyltransferase complex. Further, the present disclosure provides methods for the treatment of disease using the sulfoximine based modulators of Formula (I), or pharmaceutically acceptable salts thereof. In another aspect, the present disclosure provides methods for the modulation of N-glycosylation using the sulfoximine based modulators of Formula (I), or pharmaceutically acceptable salts thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61P 11/00 - Drugs for disorders of the respiratory system
20.
ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION IN PEDIATRIC SUBJECTS
The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection in a pediatric subject, e.g., in a pediatric subject having or at risk for developing COVID-19, wherein the methods include administering an antibody, antigen-binding fragment, or composition comprising the same to a pediatric subject. Disclosed methods include prophylactic administration for preventing SARS-CoV-2 infection or transmission, as well as treatment of a pediatric subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.
The disclosure provides enantiomeric quinoline and aza-quinazolines based on the ENPP1 modulators of Formula (I) or Formula (II) and salts thereof, and their use for the modulation of ENPP1 activity.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Methods disclosed herein involve forecasting mutations that will lead to pathogenic spread in the near future (e.g., 1 month, 2 months, 3 months, 4 months, or more). Using prior surveillance data including a previous spread of the pathogen, informative features of a mutation are identified for the pathogen and used to predict whether the mutation is likely to lead to future pathogenic spread. Thus, this enables early identification of future strains of prevalent pathogens which can be used to develop therapeutics (e.g., vaccines) before the spread has occurred.
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The disclosure relates to tuberculosis antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.
The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to S proteins of sarbecoviruses (including, in some embodiments, multiple sarbecoviruses) and, in certain embodiments, are capable of neutralizing infection by multiple sarbecoviruses.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and biological preparations and medicinal infusions for prevention and treatment of infectious diseases and disorders, viral diseases and disorders, and in the field of oncology Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines; pharmaceutical, biomedical, biological therapeutic research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical research and development; providing scientific research information in the field of pharmaceuticals, biomedicine, clinical trials, and post-market trials. Providing health and medical information; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders, and conditions; medical and pharmaceutical consultation.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza A virus hemagglutinin (HA) and can neutralize a IAV infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies or antigen-binding fragments, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an IAV infection.
Provided herein are engineered coronavirus polypeptides, polynucleotides that encode the polypeptides, vectors and host cells that comprise the polynucleotides and/or express the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered coronavirus polypeptides and fusion proteins that comprise any one or more of the foregoing.
The present disclosure provides for the treatment and/or prevention of a hepatitis B viral infection by administering to a subject a combination therapy regimen including a toll-like receptor 8 (TLR8) modulator, a dsRNA, and a PD-1/PD-L1 inhibitor.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Antiviral pharmaceuticals; immunotherapy pharmaceuticals; antiviral pharmaceuticals for use in the treatment of infectious diseases and disorders and in the field of oncology Research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Antiviral pharmaceuticals; immunotherapy pharmaceuticals for the treatment of cancer, tumors, and immune system related diseases and disorders; antiviral pharmaceuticals for use in the treatment of infectious diseases and disorders and in the field of oncology
36.
NON-VIRAL DNA VECTORS EXPRESSING ANTI-CORONAVIRUS ANTIBODIES AND USES THEREOF
The application describes methods and compositions comprising ceDNA vectors useful for the expression of anti-CoV-2 S antibodies and antigen-binding fragments thereof in a cell, tissue or subject, and methods of treatment of COVID-19 with said ceDNA vectors.
The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. In some embodiments, a sarbecovirus is from clade 1a, clade 1b, clade 2, or clade 3. In some embodiments, a sarbecovirus comprises a SARS-CoV-2, a SARS-CoV-2 G504D variant, a SARS-CoV delta variant, a SARS-CoV, or any combination thereof. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment of the present disclosure has one or more improved property, such as improved binding and/or neutralization, as compared to an antibody or antigen-binding fragment having the six CDRs of, or the VH and VL amino acid sequences as set forth, in SEQ ID NOs.:30 and 34, respectively, or as set forth in SEQ ID NOs.:22 and 26, respectively. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. In some embodiments, a sarbecovirus is from clade 1a, clade 1b, clade 2, or clade 3. In some embodiments, a sarbecovirus comprises a SARS-CoV-2, a SARS-CoV-2 G504D variant, a SARS-CoV delta variant, a SARS-CoV omicron variant, a SARS-CoV, or any combination thereof. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
EHR data records often include varying data sparsity, which renders analysis of the EHR data difficult. Methods disclosed herein involve analyzing EHR data records to generate features, such as time-binned features, in which data sparsity is reduced or removed. Thus, these time-binned features can be provided for analysis e.g., by machine learning models to predict likely infectious-disease related health outcomes for subjects.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
41.
ANTI-INFLUENZA ANTIBODIES AND COMBINATIONS THEREOF
The present disclosure relates, in part, to anti-influenza antibodies (and antigen binding fragments thereof) and combinations thereof for preventing and treating influenza infection. Presently disclosed combinations provide surprising synergistic effects and can potently prevent, inhibit, or neutralize an influenza infection, such as an influenza A virus (IAV) infection an influenza B virus (IBV) infection, or both.
The instant disclosure provides antibodies that can bind to a paramyxovirus and neutralize an infection by the paramyxovirus. The paramyxovirus can be, for example, respiratory syncytial virus, metapneumovirus, or pneumonia virus of mice. The antibodies comprise modifications in the Fc region that improve in vivo stability of the antibodies, one or more effector function of the antibodies, or both. Antibody compositions, polynucleotides that encode the antibodies, vectors, host cells, and methods of using the antibodies to prevent and/or treat a paramyxovirus infection are also provided.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.
The present disclosure relates to pharmaceutical compositions that comprise an antibody that neutralizes infection of hepatitis B virus (HBV). In addition, the present disclosure relates to the use of the pharmaceutical compositions in the treatment of HBV infection.
The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.
The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of both RABV and non-RABV lyssaviruses. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of RABV infection and infection with non-RABV lyssaviruses.
The instant disclosure provides antibodies and antigen-binding fragments that can bind to a RSV and/or MPV fusion glycoprotein and can neutralize a RSV and/or MPV infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a RSV and/or MPV infection.
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the F-protein (fusion protein) of metapneumovims (MPV). The antibodies, and antigen binding fragments thereof, neutralize infection of MPV. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in methods for detecting and checking an MPV antigen as well as in the diagnosis, treatment and prevention of MPV infection.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to S proteins of sarbecoviruses (including, in some embodiments, multiple sarbecoviruses) and, in certain embodiments, are capable of neutralizing infection by multiple sarbecoviruses.
e.g.e.g. parvovirus B19 and can neutralize a parvovirus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent a parvovirus infection.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.
in vivo in vivo half-life of the antibody or antigen-binding fragment and/or mutations in the Fc region that increase binding of the antibody or antigen-binding fragment to one or more Fc gamma receptors. Also provided are methods of using the combinations to, for example, treat or prevent an influenza virus infection, as well as compositions and kits that comprise the combinations.
e.g.e.g., Fc polypeptides, Fc polypeptide fragments, Fc fusion proteins) that comprise a variant of an IgG Fc polypeptide (or a portion or fragment thereof), which variants (and the polypeptides that comprise these variants) have one or more improved characteristics over known Fc polypeptides.
The disclosure relates to deoxyhypusine synthase (DHPS) inhibitors for use in treating or preventing respiratory virus infections, such as infection with coronaviruses, human rhinoviruses, influenza viruses, human parainfluenza viruses, respiratory syncytial viruses or human metapneumoviruses.
The disclosure relates to deoxyhypusine hydroxylase (DOHH) inhibitors for use in treating or preventing respiratory virus infections, such as infection with coronaviruses, human rhinoviruses, influenza viruses, human parainfluenza viruses, respiratory syncytial viruses or human metapneumoviruses.
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
The present disclosure provides methods for treating hepatitis D virus (HDV) infection and/or an HDV-associated disease using combination therapies, and related kits and compositions for use in such methods. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).
The disclosure provides naphthyridines based on the ENPP1 modulators of Formula (I), (Ia), (Ib), (I-1), (I-1a), (I-1b), (I-2), (I-2a), (I-2b), or (Ic) and salts thereof, and their use for the modulation of ENPP1 activity.
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
59.
COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES
The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).
The present disclosure provides antibodies that neutralize infection of influenza A virus. The disclosure also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. In addition, the disclosure provides the use of the antibodies of the disclosure in prophylaxis and treatment influenza A infection.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.
The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection, e.g., in a subject having or at risk for developing COVID-19, wherein the methods comprise administering a liquid composition containing a high concentration of an antibody, antigen-binding fragment to a subject. Disclosed methods include prophylactic administration for preventing SARS-CoV-2 infection or transmission, as well as treatment of a subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-tomoderate, severe, or critical.
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The invention also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.
Universal signatures represent generalizable features that are informative for generating predictions for different disease activities across different diseases. More specifically, one or more universal signatures are learned from data pertaining to a first disease indication and then applied to generate predictions for a one or more additional disease indications. The implementation of one or more universal signatures is useful for generating predictions for disease indications, such as disease indications involving rare or novel diseases, where it may be infeasible to develop a model due to insufficient training data.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
65.
ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF
The present disclosure relates, in part, to antibodies, and antigen-binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and, optionally, can neutralize infection hepatitis B virus (HBV), and further optionally, of hepatitis delta virus (HDV). Presently disclosed antibodies and antigen-binding fragments have advantageous production characteristics, such as reduced formation of aggregates and/or improved production titer in transformed host cells, as compared to a reference antibody or antigen-binding fragment. The present disclosure also relates to fusion proteins that comprise an antigen-binding fragment, and to nucleic acids that encode and cells that produce such antibodies, antigen-binding fragments, and fusion proteins. In addition, the present disclosure relates to the use of the antibodies, antigen-binding fragments, fusion proteins, and related polynucleotides, vectors, host cells, and compositions of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D. Also provided are combination therapies comprising (i) an antibody or antigen-binding fragment and (ii) an agent that is an inhibitor of HBV gene expression and/or that reduces HBV antigenic load.
The present disclosure relates to methods of inhibiting replication of a respiratory virus, and methods of treating or preventing a respiratory virus infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a N-glycosylation pathway inhibitor.
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
67.
HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07D 207/33 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
C07D 215/44 - Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
C07D 215/54 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
69.
VIROLOGICAL AND MOLECULAR SURROGATES OF RESPONSE TO SARS-COV-2 NEUTRALIZING ANTIBODY SOTROVIMAB
Methods involve deployment of a biomarker panel for classifying patients as responders/non-responders to a SARS-CoV-2 therapeutic (e.g., Sotrovimab) and/or classifying patients as at risk or not at risk for severe infectious disease. Using whole transcriptome data, example biomarker panels are deployed to analyze expression values of certain genes. Such biomarker panels outperform quantifiable clinical laboratory markers (e.g., lymphocytes or neutrophil-lymphocyte ratio), thereby indicating systemic immune response, as evidenced by expression values of biomarkers, provide powerful predictive insights.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The disclosure provides enantiomeric quinoline and aza-quinazolines based on the ENPP1 modulators of Formula (I) or Formula (II) and salts thereof, and their use for the modulation of ENPP1 activity.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides compounds or salts of Formula (I) which modulate Beclin-l/Bcl-2 protein- protein interactions. These interactions induce autophagy and are useful for treating a variety of indications, including cancer, infection immunity, neurodegeneration, and ageing.
C07D 213/10 - Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from acetaldehyde or cyclic polymers thereof
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
72.
ANTIBODIES BINDING TO PLASMODIUM CIRCUMSPOROZOITE PROTEIN AND USES THEREOF
The present invention provides antibodies targeting Plasmodium sporozoites, in particular plasmodium circumsporozoite protein. The invention also provides nucleic acids that encode such antibodies. In addition, the invention provides the use of the antibodies of the invention in prophylaxis and treatment malaria.
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
The present disclosure provides antibody combinations and related methods for treating a SARS-CoV-2 infection in a subject or for manufacturing a medicament for the treatment of a SARS-CoV-2 infection. In some aspects, therapy comprises two antibodies that bind compete for binding to a SARS-CoV-2 surface (S) glycoprotein monomer. The antibody combinations can potently neutralize SARS-CoV-2, can broadly neutralize SARS-CoV-2 variants, and are resistant to viral breakthrough. Antibody compositions comprising such combinations are also provided.
The disclosure relates to tuberculosis antigens and vectors for delivering the antigens. The disclosure also relates to immunogenic compositions comprising the same, and their uses.
The present disclosure provides methods for producing cytomegalovirus (CMV) viral vectors. The present disclosure also provides methods for modifying host cells for use in producing CMV viral vectors.
e.g.e.g.e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.
e.g.e.g.e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.
Provided herein are engineered coronavirus polypeptides, polynucleotides that encode the polypeptides, vectors and host cells that comprise the polynucleotides and/or express the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusion proteins that comprise any one or more of the foregoing.
Methods disclosed herein involve forecasting mutations that will lead to pathogenic spread in the near future (e.g., 1 month, 2 months, 3 months, 4 months, or more). Using prior surveillance data including a previous spread of the pathogen, informative features of a mutation are identified for the pathogen and used to predict whether the mutation is likely to lead to future pathogenic spread. Thus, this enables early identification of future strains of prevalent pathogens which can be used to develop therapeutics (e.g., vaccines) before the spread has occurred.
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16B 20/40 - Population geneticsLinkage disequilibrium
82.
ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
The present disclosure relates to pharmaceutical compositions that comprise an antibody that neutralizes infection of hepatitis B virus (HBV). In addition, the present disclosure relates to the use of the pharmaceutical compositions in the treatment of HBV infection.
Provided herein are engineered polypeptides (e.g., Fc polypeptides, Fc polypeptide fragments, Fc fusion proteins, antibodies, and the like) that comprise a variant of an IgG Fc polypeptide (or a portion or fragment thereof), which variants (and the polypeptides that comprise these variants) have one or more improved characteristics over known Fc polypeptides.
The present disclosure provides for the treatment and/or prevention of a hepatitis B viral infection by administering to a subject a combination therapy regimen including a toll-like receptor 8 (TLR8) modulator, a dsRNA, and a PD‑1/PD‑L1 inhibitor.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The application describes methods and compositions comprising ceDNA vectors useful for the expression of anti-CoV-2 S antibodies and antigen-binding fragments thereof in a cell, tissue or subject, and methods of treatment of COVID-19 with said ceDNA vectors.
The present disclosure provides methods for treating HBV infection using an siRNA that targets an HBV gene. In some embodiments, the method for treating HBV involves co-administration of siRNA with PEG-INFα.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
87.
COMPOSITIONS AND METHODS FOR TREATMENT OF INFLUENZA A INFECTION
The present disclosure provides antibodies, antibody compositions, and methods for use in prophylaxis and treatment of influenza A infection. In certain embodiments, a single administration of a presently disclosed antibody or antibody composition is useful to protect against and/or treat an influenza A infection for a full flu season.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to S proteins of sarbecoviruses (including, in some embodiments, multiple sarbecoviruses) and, in certain embodiments, are capable of neutralizing infection by multiple sarbecoviruses.
The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV)vaccines. The present disclosure also relates to viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines described herein. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area are also provided herein.
The instant disclosure provides antibodies that can bind to a paramyxovirus and neutralize an infection by the paramyxovirus. The paramyxovirus can be, for example, respiratory syncytial virus, metapneumovirus, or pneumonia virus of mice. The antibodies comprise modifications in the Fc region that improve in vivo stability of the antibodies, one or more effector function of the antibodies, or both. Antibody compositions, polynucleotides that encode the antibodies, vectors, host cells, and methods of using the antibodies to prevent and/or treat a paramyxovirus infection are also provided.
The present disclosure relates to pharmaceutical compositions that comprise an antibody that neutralizes infection of hepatitis B virus (HBV). In addition, the present disclosure relates to the use of the pharmaceutical compositions in the treatment of HBV infection.
The present disclosure provides antibody combinations and related methods for treating a SARS-CoV-2 infection in a subject or for manufacturing a medicament for the treatment of a SARS-CoV-2 infection. In some aspects, a therapy, composition, or combination can include two or three antibodies that bind to different epitopes on a SARS-CoV-2 surface (S) glycoprotein. The antibody combinations can potently neutralize SARS-CoV-2. Antibody compositions comprising such combinations are also provided.
The present invention provides antibodies that neutralize infection of influenza A virus. The invention also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. In addition, the invention provides the use of the antibodies of the invention in prophylaxis and treatment influenza A infection.
The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the F-protein (fusion protein) of metapneumovirus (MPV). The antibodies, and antigen binding fragments thereof, neutralize infection of MPV. The invention also relates to nucleic acids that encode, and to cells that express such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments in methods for detecting and checking an MPV antigen as well as in the diagnosis, treatment and prevention of MPV infection.
The present disclosure provides antibodies that neutralize infection of influenza A virus. The disclosure also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. In addition, the disclosure provides the use of the antibodies of the disclosure in prophylaxis and treatment influenza A infection.
The instant disclosure provides antibodies and antigen binding fragments thereof that can bind to S proteins of multiple betacoronaviruses and, in certain embodiments, are capable of neutralizing infection by multiple betacoronaviruses.
The present disclosure relates, in part, to anti-influenza antibodies (and antigenbinding fragments thereof) and combinations thereof for preventing and treating influenza infection. Presently disclosed combinations provide surprising synergistic effects and can potently prevent, inhibit, or neutralize an influenza infection, such as an influenza A virus (IAV) infection an influenza B virus (IBV) infection, or both.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza A virus hemagglutinin (HA) and can neutralize a IAV infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies or antigen-binding fragments, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an IAV infection.
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.
